促甲状腺激素释放激素类似物（RX77368）在运动神经元病中的亚急性给药：一项开放性研究。
Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study.
作者信息
Modarres-Sadeghi H, Rogers H, Emami J, Guiloff R J
机构信息
Department of Neurology, Charing Cross and Westminster Medical School, Westminster Hospital, London, UK.
出版信息
J Neurol Neurosurg Psychiatry. 1988 Sep;51(9):1146-57. doi: 10.1136/jnnp.51.9.1146.
Sixteen patients with motor neuron disease received RX77368, a TRH analogue, IV, repeatedly over 1-12 weeks (median 2 weeks). Slight to moderate improvement in bulbar function, particularly speech, was reproduced or persisted with repeated infusions in 8 of 12 responders over a median of 18 days (range 14-90) during the period of study. Cramps (5/9) and spasticity (5/8) improved for a median of 14 days (range 7-35) and 7 days (range 2-14) respectively. The highest benefit/side effect ratio was seen with 0.2 mg/kg (0.15 mg/kg in those with severe bulbar palsy) every 3-4 days. Long term studies with this analogue in MND are indicated.
16例运动神经元病患者接受了TRH类似物RX77368静脉注射，在1至12周（中位数为2周）内反复给药。在研究期间，12例有反应者中的8例在重复输注后，延髓功能（尤其是言语功能）出现轻微至中度改善，这种改善重现或持续，持续时间中位数为18天（范围14 - 90天）。痉挛（5/9）和痉挛状态（5/8）分别在中位数为14天（范围7 - 35天）和7天（范围2 - 14天）的时间内得到改善。每3 - 4天给予0.2 mg/kg（严重延髓麻痹患者为0.15 mg/kg）时，获益/副作用比最高。表明需要对该类似物在运动神经元病中的长期研究。
Zotero 插件